Payment overview · 2025
General Payments
$917.91
47 reported records · 14 companies
Healthcare provider profile · identity verified
Robert Adam Bendorf, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HARLAN, IA · NPI 1770746620
Verified facts
What the public records show
CMS Open Payments records show Robert Adam Bendorf, D.O. received $917.91 in general payments during 2025 across 47 reported records.
Lilly USA, LLC accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Jardiance, Mounjaro, Ozempic, Trintellix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $305.60 | 33.3% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $147.93 | 16.1% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $120.63 | 13.1% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.68 | 11.2% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.98 | 4.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $32.43 | 3.5% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $32.06 | 3.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.03 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.28 | 2.5% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.10 | 2.4% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $19.35 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.51 | 1.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.43 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.90 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $917.91 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $284.29 | 14 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $284.29 | 14 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $120.63 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.52 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.03 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.98 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $32.43 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $30.06 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| KOSELUGO Normalized: koselugo |
Drug | Alexion Pharmaceuticals, Inc. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| Zilretta Normalized: zilretta |
Drug | Pacira Pharmaceuticals Incorporated | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 64 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
139 | 25 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 352 | 57 |
| Furosemide | Furosemide | 259 | 42 |
| Gabapentin | Gabapentin | 233 | 39 |
| Lisinopril | Lisinopril | 212 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 40 |
| Omeprazole | Omeprazole | 180 | 43 |
| Potassium Chloride | Potassium Chloride | 171 | 30 |
| Losartan Potassium | Losartan Potassium | 166 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 27 |
| Metformin Hcl | Metformin Hcl | 163 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 23 |
| Warfarin Sodium | Warfarin Sodium | 143 | suppressed |
| Eliquis | Apixaban | 139 | 25 |
| Tramadol Hcl | Tramadol Hcl | 139 | 55 |
| Simvastatin | Simvastatin | 114 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 16 |
| Ozempic | Semaglutide | 97 | 14 |
| Montelukast Sodium | Montelukast Sodium | 92 | 13 |
| Allopurinol | Allopurinol | 86 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 12 |
| Alprazolam | Alprazolam | 80 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 25 |
| Sertraline Hcl | Sertraline Hcl | 76 | suppressed |
| Jardiance | Empagliflozin | 64 | 12 |
| Baclofen | Baclofen | 63 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 20 |
| Entresto | Sacubitril/Valsartan | 62 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 60 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | suppressed |
| Famotidine | Famotidine | 53 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 11 |
| Metformin Hcl Er | Metformin Hcl | 52 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Lorazepam | Lorazepam | 50 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | suppressed |
| Meloxicam | Meloxicam | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Celecoxib | Celecoxib | 42 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 12 |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Prednisone | Prednisone | 39 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Azithromycin | Azithromycin | 33 | 31 |
| Ondansetron Odt | Ondansetron | 31 | 17 |
| Torsemide | Torsemide | 30 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 23 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 18 |
| Azathioprine | Azathioprine | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Humira Pen | Adalimumab | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $917.91 · 47 records | Lilly USA, LLC | ABRYSVO, CAPVAXIVE, COMIRNATY, ENTRESTO, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, JOURNAVX, KOSELUGO, LEQVIO, MOUNJARO, Ozempic, PREVNAR 20, REXULTI, Rybelsus, SHINGRIX, TRINTELLIX, VAXELIS, VAXNEUVANCE, Veozah, Wegovy, ZEPBOUND, Zilretta | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error